Letters
Cardiovascular diseases Pharmacology
Volume 186 - Issue 2

Does the presence of heart failure alter prescribing of drug therapy after myocardial infarction?

Author:  Henry Krum

Med J Aust 2007; 186 (2): 99-101. || doi: 10.5694/j.1326-5377.2007.tb00818.x
Published online: 15 January 2007
Download PDF (393 KB)
Share: Share on Blue Sky Share on Facebook Share on LinkedIn Share by email

In reply: We thank Bailey and Naganathan for their thoughtful viewpoint regarding prescribing according to clinical trial criteria. We agree that prescribing in the real world often involves complex decision making, taking into account age, comorbidities, concomitant medications and other factors, whereby guidance regarding individual patients cannot readily be extracted from clinical trial literature. This may certainly contribute to underutilisation of evidence-based drug treatment.1 Nevertheless, several analyses support the contention that physicians who more closely adhere to evidence-based guidelines (which in turn are derived from randomised clinical trials) produce better outcomes for their patients.2,3 Therefore, we would still advocate prescribing as closely as possible to guideline recommendations, while acknowledging that these recommendations may not always be readily applicable to every patient.

Author

  • Henry Krum1
  • 1. NHMRC Centre of Clinical Research Excellence in Therapeutics, Monash University and The Alfred Hospital, Melbourne, VIC.

Correspondence: henry.krum@med.monash.edu.au

References

View this article on Wiley Online Library